Jci_page_head_homepage_01 Jci_page_head_homepage_02
Mingquan Zheng, Alistair J. Ramsay, Myles B. Robichaux, Karen A. Norris, Corrine Kliment, Christopher Crowe, Rekha R. Rapaka, Chad Steele, Florencia McAllister, Judd E. Shellito, Luis Marrero, Paul Schwarzenberger, Qiu Zhong, Jay K. Kolls
Published in Volume 115, Issue 12
J Clin Invest. 2005; 115(12):3536–3544 doi:10.1172/JCI26306
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1

Humoral responses after pOVA or pOVA/CD40L DNA vaccination. (A) Schema of prime-boost vaccination protocol. DNA vectors used were pOVA, pOVA/CD40L, pBUDCE4 (as empty vector), or pCD40L. Adenovirus boosting was carried out with AdOVA, AdOVA and AdCD40L, AdLuc, or AdLuc and AdCD40L. Anti-OVA IgG2a (B) and IgG1 (C) responses after 3 successive intramuscular DNA vaccinations with pOVA or pOVA/CD40L in CD4-depleted and CD4-replete mice n = 6–8 per group. All data are mean titer ± SEM. *P < 0.05 compared with control. A line denotes the limit of detection in the ELISA.